Sangamo Therapeutics (SGMO) Return on Invested Capital (2016 - 2025)
Historic Return on Invested Capital for Sangamo Therapeutics (SGMO) over the last 9 years, with Q3 2025 value amounting to 8.4%.
- Sangamo Therapeutics' Return on Invested Capital fell 39500.0% to 8.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.4%, marking a year-over-year decrease of 39500.0%. This contributed to the annual value of 1.96% for FY2024, which is 5400.0% down from last year.
- Sangamo Therapeutics' Return on Invested Capital amounted to 8.4% in Q3 2025, which was down 39500.0% from 5.11% recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Return on Invested Capital registered a high of 0.27% during Q1 2021, and its lowest value of 8.4% during Q3 2025.
- Moreover, its 5-year median value for Return on Invested Capital was 0.74% (2023), whereas its average is 2.5%.
- In the last 5 years, Sangamo Therapeutics' Return on Invested Capital plummeted by -56900bps in 2024 and then surged by 13100bps in 2025.
- Sangamo Therapeutics' Return on Invested Capital (Quarter) stood at 0.47% in 2021, then plummeted by -42bps to 0.67% in 2022, then tumbled by -269bps to 2.47% in 2023, then plummeted by -36bps to 3.35% in 2024, then crashed by -151bps to 8.4% in 2025.
- Its Return on Invested Capital stands at 8.4% for Q3 2025, versus 5.11% for Q2 2025 and 5.92% for Q1 2025.